Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations.
In the first part of this study we have shown how the serum levels of four selected tumour markers, namely tissue polypeptide antigen (TPA), carcino-embryonic antigen (CEA), hyaluronic acid (HA) and ferritin, display patterns characteristic of mesothelioma (M) or bronchogenic carcinoma (BC) in asbestos-exposed workers, and we hypothesize that the differences in marker patterns correspond to differences in carcinogenesis mechanisms. In a preliminary study, we found these specific marker patterns in 5/19 exposed workers of whom only one demonstrated any radiological signs of disease. Thus these specific marker patterns may be early events, occurring long (possibly years) before the classical radiological signs of exposure to asbestos. Accordingly they afford an optimal opportunity for prevention which should be adapted to the carcinogenesis mechanism as it is revealed by the marker pattern; it is aimed at antagonizing free radical carcinogenesis in all persons with TPA levels in excess of 100 U/l or Ferritin in excess of 400 ng/ml, and at inhibiting chemical carcinogenesis in those having elevated CEA levels (over 3 ng/ml). The mechanisms involved in these inhibitory processes are described and discussed, as well as the practical implementations that proceed from them. A prevention trial is now being started among 300 active and retired workers of an asbestos-cement works in northern France; the design of the study is presented. This prevention programme should be maintained over many years and holds a strong potential for reducing the untoward effects of exposure to asbestos.
Pluygers
E
E
UNEP-RISCAPE, Unit for Evaluation and Prevention of Carcinogenesis Risks of Occupational and Environmental Origin, Haine-Saint-Paul, Belgium.
Baldewyns
P
P
Minette
P
P
Beauduin
M
M
Gourdin
P
P
Robinet
P
P
D000111:Acetylcysteine / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000097:blood; D001194:Asbestos / Q000009:adverse effects*; D001205:Ascorbic Acid / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D002283:Carcinoma, Bronchogenic / Q000097:blood / Q000517:prevention & control*; D002338:Carotenoids / Q000097:blood / Q000627:therapeutic use; D015331:Cohort Studies; D005293:Ferritins / Q000097:blood; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood; D008137:Longitudinal Studies; D008175:Lung Neoplasms / Q000097:blood / Q000517:prevention & control*; D008297:Male; D008654:Mesothelioma / Q000097:blood / Q000517:prevention & control*; D008875:Middle Aged; D009784:Occupational Diseases / Q000097:blood / Q000517:prevention & control*; D016273:Occupational Exposure; D010455:Peptides / Q000097:blood; D012256:Riboflavin / Q000627:therapeutic use; D012643:Selenium / Q000097:blood / Q000627:therapeutic use; D019396:Tissue Polypeptide Antigen; D014801:Vitamin A / Q000097:blood; D014810:Vitamin E / Q000097:blood / Q000627:therapeutic use; D019207:beta Carotene
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010455:Peptides; D019396:Tissue Polypeptide Antigen; D019207:beta Carotene; D014801:Vitamin A; D001194:Asbestos; D014810:Vitamin E; D002338:Carotenoids; D006820:Hyaluronic Acid; D005293:Ferritins; D012643:Selenium; D001205:Ascorbic Acid; D012256:Riboflavin; D000111:Acetylcysteine